Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer

作者：Kim Insoo; Byeon Hyeong Jun; Kim Tae Hyung; Lee Eun Seong; Oh Kyung Taek; Shin Beom Soo; Lee Kang Choon; Youn Yu Seok^*

来源：Biomaterials, 2013, 34(27): 6444-6453.

DOI：10.1016/j.biomaterials.2013.05.018

• Porous microparticles
• Inhalation
• TNF-related apoptosis-inducing ligand
• Doxorubicin
• Lung cancer
• Synergism

Inhalable highly porous large PLGA microparticles with incorporated doxorubicin and surface-attached with TRAIL (TRAIL/Dox PLGA MP) were fabricated using a w/o/w double emulsification method using ammonium bicarbonate as a gas-foaming agent for the treatment of lung cancer. The TRAIL/Dox PLGA MP produced were highly porous and 11.5 +/- 0.4 mu m in diameter, and the loading efficiencies of Dox and TRAIL were 86.5 +/- 6.5% and 91.8 +/- 2.4%, respectively. TRAIL and doxorubicin were gradually released by TRAIL/Dox PLGA over 7 days, and pulmonary administration resulted in the deposition of TRAIL/Dox PLGA MP in mouse lungs, and they remained in situ for up to a week. The anti-tumor efficacy of pulmonary administered TRAIL/Dox PLGA MP was evaluated in a BALB/c nu/nu mice mouse model of H226 cell metastasis. Tumors in H226-implanted mice treated with TRAIL/Dox PLGA MP were markedly smaller and fewer in number than mice treated with TRAIL or Dox PLGA MP alone. Furthermore, this improved performance was found to be due to the synergistic apoptotic effects of the two drugs. We believe that TRAIL/Dox PLGA MP offer a promise of a sustained-release, long-acting, inhalable anti-lung cancer agent. Furthermore, the synergism observed between TRAIL and doxorubicin suggests that the doxorubicin dosage could be substantially reduced and its side effects minimized.

• 出版日期2013-9